Period:
Draw Mode:
| Volume | 805,939 |
|
|||||
| News | - | ||||||
| Day High | 9.45 | Low High |
|||||
| Day Low | 8.92 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Anavex Life Sciences Corporation | AVXL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.10 | -1.08% | 9.16 | 13:49:10 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 9.34 | 8.92 | 9.45 | 9.26 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,597 | 805,939 | $ 9.12 | $ 7,352,121 | - | 7.13 - 15.24 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:49:09 | 50 | $ 9.16 | USD |
Anavex Life Sciences Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 714.77M | 78.03M | 75.68M | $ - | $ - | -0.62 | -15.00 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 13.00% |
Anavex Life Sciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVXL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.63 | 9.86 | 8.92 | 9.45 | 1,328,029 | -0.47 | -4.88% |
| 1 Month | 10.38 | 10.45 | 8.535 | 9.61 | 1,069,919 | -1.22 | -11.75% |
| 3 Months | 8.45 | 11.925 | 8.01 | 10.11 | 1,174,618 | 0.71 | 8.4% |
| 6 Months | 9.58 | 15.24 | 7.63 | 10.52 | 1,673,247 | -0.42 | -4.38% |
| 1 Year | 12.89 | 15.24 | 7.13 | 10.39 | 1,255,508 | -3.73 | -28.94% |
| 3 Years | 2.46 | 31.50 | 2.23 | 12.64 | 1,460,677 | 6.70 | 272.36% |
| 5 Years | 2.69 | 31.50 | 1.25 | 10.84 | 1,085,038 | 6.47 | 240.52% |
Anavex Life Sciences Description
| Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases. |